<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374036</url>
  </required_header>
  <id_info>
    <org_study_id>0305603</org_study_id>
    <nct_id>NCT00374036</nct_id>
  </id_info>
  <brief_title>Metastatic Gastric Cancer FFCD 03-07</brief_title>
  <official_title>Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of 2 different sequences of
      polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally
      advanced or metastatic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the effectiveness of two different sequences of polychemotherapy among carrying
      patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until therapeutic failure : to make pass TET from 15 weeks with ECC in first line to 20 weeks with FOLFIRI in first line</measure>
    <time_frame>20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of total survival and survival without progression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of objective answers in first and second line</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of treated patients in second line</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control time of the disease</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerance, the quality of life, duration of hospitalization</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ECC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ECC</intervention_name>
    <description>capecitabine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Irinotecan</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age = 18 years old

          -  patients carrying a adenocarcinoma of the stomach or cardia histologically proven

          -  locally advanced tumour which may not be treated surgically or metastatic tumour

          -  the patients having a stenosante tumour responsible for a disphagy had to have a
             tumoral ablation or a prosthesis or a probe of food,

          -  measurable lesions according to criteria RECIST (specify measurement by spiral scanner
             of largest diameter of with less the one lesion of size higher than 1 cm) or
             appraisable but nonmeasurable (lesions &lt; 1 cm, ascite, pleural effusion...)

          -  general state WHO &lt; 2

          -  absence of insufficiency cardiac or coronary symptomatic

          -  absence of previous chemotherapy other that auxiliary stopped since more than 6 months

          -  filled questionnaires QLQ C30 and STO-22

          -  PNN = 1500/mm3, haemoglobin ≥ 10g/dl, plates= 100 000/mm3

          -  creatinin ≤ 110 micromol/l

          -  bilirubin ≤ 35 micromol/l

        Exclusion Criteria:

          -  disphagy or intestinal obstruction incompatible with a treatment per os or by a probe
             of food

          -  pregnant or nursing woman

          -  previous of cardiac toxicity to the 5FU or to the anthracyclines

          -  radiotherapy less than 3 weeks before inclusion, whatever the site

          -  other evolutionary cancer threatening the short-term life

          -  metastasis cerebral or méningée known (without obligation to seek it)

          -  impossibility of regular follow-up for psychological, social, family or geographical
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosine GUIMBAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU TOULOUSE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>October 10, 2011</last_update_submitted>
  <last_update_submitted_qc>October 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>stomach cancer metastatic</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

